Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2001

View Archived Issues

Old drugs may be new therapy for Creutzfeldt-Jakob and other prion diseases

Studies demonstrate antiatherosclerotic effects of lutein

Amsterdam Molecular Therapeutics steps up LPL gene therapy program

CV Therapeutics commences phase II clinical trial of CVT-3146

Nycomed Amersham Imaging and Affitech expand human antibody agreement

CA4P development program continues as planned

Pharmacopeia and Eos Biotechnology agree to merge

Helivax demonstrates safety, immunogenicity in phase Ib trial

Two centers added to 12-week study of Neotrofin in spinal cord injury

Enbrel shows positive results in phase II clinical study of psoriasis

Invitrogen to market lentiviral vectors from Cell Genesys

Aventis highlights pipeline progress for first half of 2001

Oral suspension formulation of Trileptal soon to be available in Europe

Potent, orally bioavailable FTase inhibitors discovered at Aventis

Pharmacia presents a potent MMP inhibitor at ACS meeting in Chicago

Novel cytokine production inhibitors highlighted at the ongoing ACS meeting

Demegen receives grant in support of P-113D development for cystic fibrosis infections

Selective epoxyketone inhibitors developed at Yale University

BMS patents compounds having unique dopaminergic and serotonergic activity

Potent and selective integrin inhibitors reported by Celltech

Bone-targeting compounds in the Ariad pipeline

NeuroSearch patents nACh receptor modulators

Research at Amgen leads to the discovery of new integrin antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...